Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP)

Coeptis Therapeutics Holdings, Inc. operates as a biopharmaceutical company, focusing on the acquisition, development, and commercialization of cell therapy technologies aimed at treating cancer and other diseases. The company's business model revolves around advancing its current product portfolio and exploring strategic partnerships to enhance its therapeutic offerings. Coeptis Therapeutics Holdings, Inc. was originally incorporated in the British Virgin Islands and later domesticated to the State of Delaware, changing its name from Bull Horn Holdings Corp. to its current name in October 2022. The company acquired its primary operating subsidiary, Coeptis Therapeutics, Inc., through a merger, which now continues its business operations as a wholly-owned subsidiary.

Coeptis Therapeutics Holdings, Inc. generates revenue through the development and potential commercialization of its therapeutic products. The company's primary products include CD38-GEAR-NK, CD38-Diagnostic, and the SNAP-CAR Platform, which are designed to address various medical conditions, particularly in the field of oncology. The general customer base for these products includes healthcare providers, hospitals, and patients suffering from conditions such as multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. The company also explores partnerships with other biopharmaceutical companies to expand its product portfolio and enhance its development capabilities.

• CD38-GEAR-NK: This product is designed to protect CD38+ NK cells from destruction by anti-CD38 monoclonal antibodies. It is an autologous, NK cell-based therapeutic derived from a patient's own cells and gene-edited to enable combination therapy with anti-CD38 mAbs. The target market for CD38-GEAR-NK includes patients with CD38-related cancers such as multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. The company believes this product has the potential to minimize the risks and side effects from CD38-positive NK cell fratricide.

• CD38-Diagnostic: This product is an in vitro diagnostic tool aimed at analyzing whether cancer patients might be appropriate candidates for anti-CD38 mAb therapy. It is intended to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 mAb therapies, either as monotherapy or in combination with CD38-GEAR-NK. The target market for CD38-Diagnostic includes healthcare providers and patients with B cell malignancies with high CD38 expression.

• SNAP-CAR Platform: The SNAP-CAR technology is a universal therapeutic platform that involves co-administering CAR T-cells with one or more antibody adaptors that bind to tumor cells. This platform is being developed to target solid tumors and potentially offer several advantages over standard CAR-T treatments, including reduced potential toxicity and reduced cancer relapse. The target market for the SNAP-CAR Platform includes patients with solid tumors, and the company aims to expand the potential impact of SNAP-CAR by performing in vitro screening of many additional antigen-antibody combinations in hematological and/or solid tumors.

Coeptis Therapeutics Holdings, Inc. operates in the competitive biopharmaceutical industry, where it faces competition from other companies developing cell therapy technologies and diagnostic tools. Key competitors include larger pharmaceutical companies with extensive resources and smaller biotech firms focusing on innovative therapies. The company's competitive advantages lie in its strategic partnerships, exclusive licensing agreements, and the potential of its proprietary technologies to address unmet medical needs. For instance, the SNAP-CAR Platform aims to provide a highly programmable therapeutic platform that could deliver several potential advantages over standard CAR-T treatments, positioning the company favorably in the market.

The company's general customer base includes healthcare providers, hospitals, and patients suffering from various cancers and other diseases. While specific customer names are not provided, the target market for Coeptis Therapeutics Holdings, Inc.'s products encompasses a broad range of medical professionals and patients in need of advanced therapeutic solutions. The company's focus on developing innovative cell therapy technologies positions it to serve a growing demand for effective treatments in the oncology and other disease areas.